Join Growin Stock Community!

科懋6496.TW Overview

TW StockBiotech. & Medical
(No presentation for 6496)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

科懋（6496）Overall Performance

科懋（6496）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

科懋（6496） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

科懋（6496）Key Information

科懋（6496）Profile

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.

科懋（6496）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
40.10%
Net Margin
-20.39%
Revenue Growth (YoY)
4.22%
Profit Growth (YoY)
-5.74%
3-Year Revenue Growth
18.62%
3-Year Profit Growth
18.01%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
40.10%
Net Margin
-20.39%
Revenue Growth (YoY)
4.22%
Profit Growth (YoY)
-5.74%
3-Year Revenue Growth
18.62%
3-Year Profit Growth
18.01%
default symbol

6496

科懋

27.10D

2.95%

(0.03)

  • When is 6496's latest earnings report released?

    The most recent financial report for 科懋 (6496) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6496's short-term business performance and financial health. For the latest updates on 6496's earnings releases, visit this page regularly.

  • What is the operating profit of 6496?

    According to the latest financial report, 科懋 (6496) reported an Operating Profit of -33.38M with an Operating Margin of -11.96% this period, representing a decline of 108.08% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6496's revenue growth?

    In the latest financial report, 科懋 (6496) announced revenue of 279.22M, with a Year-Over-Year growth rate of 15.99%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6496 have?

    At the end of the period, 科懋 (6496) held Total Cash and Cash Equivalents of 185.34M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6496 go with three margins increasing?

    In the latest report, 科懋 (6496) did not achieve the “three margins increasing” benchmark, with a gross margin of 40.29%%, operating margin of -11.96%%, and net margin of -14.06%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6496's profit trajectory and future growth potential.

  • Is 6496's EPS continuing to grow?

    According to the past four quarterly reports, 科懋 (6496)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6496?

    科懋 (6496)'s Free Cash Flow (FCF) for the period is 15.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 796.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.